Analysts’ price target changes for Tuesday, August 22nd:
BHP Billiton plc (LON:BLT) was given a GBX 1,400 ($18.17) target price by analysts at S&P Global. The firm currently has a neutral rating on the stock.
Cardiome Pharma Corporation (NASDAQ:CRME) (TSE:COM) was given a $10.00 target price by analysts at HC Wainwright. The firm currently has a buy rating on the stock.
Fiat Chrysler Automobiles NV (BIT:F) was given a €14.00 ($16.47) price target by analysts at Morgan Stanley. The firm currently has a buy rating on the stock.
Fabrinet (NYSE:FN) was given a $50.00 price target by analysts at Northland Securities. The firm currently has a buy rating on the stock.
Total SA (EPA:FP) was given a €48.00 ($56.47) price target by analysts at Societe Generale. The firm currently has a buy rating on the stock.
Marshalls plc (LON:MSLH) had its target price increased by Canaccord Genuity from GBX 375 ($4.87) to GBX 415 ($5.39). They currently have a hold rating on the stock.
Aurubis AG (ETR:NDA) was given a €54.00 ($63.53) target price by analysts at Morgan Stanley. The firm currently has a sell rating on the stock.
Poet Technologies (NASDAQ:POETF) was given a $2.00 target price by analysts at HC Wainwright. The firm currently has a buy rating on the stock.
Prosiebensat 1 Media SE (ETR:PSM) was given a €42.00 ($49.41) price target by analysts at Nord/LB. The firm currently has a buy rating on the stock.
Secure Trust Bank Plc (LON:STB) had its price target trimmed by Canaccord Genuity from GBX 2,585 ($33.56) to GBX 2,470 ($32.07). Canaccord Genuity currently has a buy rating on the stock.
Symrise AG (FRA:SY1) was given a €62.00 ($72.94) target price by analysts at Societe Generale. The firm currently has a neutral rating on the stock.
System1 Group PLC (LON:SYS1) had its target price cut by Canaccord Genuity from GBX 955 ($12.40) to GBX 730 ($9.48). The firm currently has a buy rating on the stock.
TrovaGene (NASDAQ:TROV) was given a $4.00 target price by analysts at Maxim Group. The firm currently has a buy rating on the stock. The analysts wrote, “Trovagene announced positive preclinical data for PCM-075, an oral polo-like kinase 1 (PLK1) inhibitor demonstrating synergy (80%) with a histone deacetylase (HDAC) inhibitor in aggressive double-hit non-Hodgkin lymphoma (NHL). B-cell lymphoma has the highest fold overexpression of PLK1 (56X).””
TherapeuticsMD (NASDAQ:TXMD) was given a $10.00 price target by analysts at Deutsche Bank AG. The firm currently has a buy rating on the stock.
